Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Rand… (NCT00567788) | Clinical Trial Compass
UnknownNot Applicable
Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study
Singapore60 participantsStarted 2006-07
Plain-language summary
This is a randomized observer-masked cross-over study to compare the intraocular pressure (IOP) reducing effect of latanoprost with bimatoprost in subjects with chronic angle closure glaucoma (CACG) with raised IOP. Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline. The study will be carried out in at least 2 Singapore hospitals.
Who can participate
Age range40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Unilateral or bilateral CACG
✓. Age more than or equal to 40 years old
✓. Informed consent obtained at pre-study visit for all patients
Exclusion criteria
✕. Secondary glaucoma such as uveitic or neovascular glaucoma
✕. One eye eligible and fellow eye on unsuitable glaucoma treatment for this trial
✕. IOP \> 36 mmHg at Pre-study visit
✕. Advanced glaucoma at risk of progression. This is defined as vertical cup-disc ratio \> 0.9 and/or central visual field loss with a sensitivity of \< 10 dB in any of the 4 visual field test points closest to fixation
✕. Ocular infection or inflammation (except when related to peripheral iridotomy) within 3 months of the prestudy visit
✕. On more than two anti-glaucoma medications
✕. Previous intraocular surgery apart from laser peripheral iridotomy
What they're measuring
1
The primary endpoint is defined as IOP reduction from baseline measurement (week 0) to the measurement at week 6 at each treatment period.